First Shoulder Arthroplasty Surgeries Using Stryker’s Blueprint® Mixed Reality Guidance System Completed at Mayo Clinic in Minnesota and at St. Joseph’s Health Care London in Canada

2024-01-10
First Shoulder Arthroplasty Surgeries Using Stryker’s Blueprint® Mixed Reality Guidance System Completed at Mayo Clinic in Minnesota and at St. Joseph’s Health Care London in Canada
Preview
来源: Business Wire
'Mixed reality technology offers important benefits to patients'
First Shoulder Arthroplasty Surgeries Using Stryker’s Blueprint® Mixed Reality Guidance System Completed at Mayo Clinic in Minnesota and at St. Joseph’s Health Care London in Canada
Preview
来源: Business Wire
KALAMAZOO, Mich.--(BUSINESS WIRE)--Stryker (NYSE:SYK), one of the world’s leading medical technology companies, today announced that the first shoulder arthroplasty surgeries using Blueprint® Mixed Reality (MR) Guidance have been successfully completed by Dr. Joaquin Sanchez-Sotelo, MD, PhD, Consultant and Professor of Orthopedic Surgery at Mayo Clinic in Rochester, Minn., and Dr. George Athwal at St. Joseph’s Health Care London, Canada.
“Mixed reality technology offers important benefits to patients,” said Dr. Sanchez-Sotelo, one of the Blueprint design surgeons. “This technology allows the surgeon to plan and execute the surgery based on precise images of the patient’s shoulder, thereby minimizing the risk of improper placement of the implant. This is individualized care tailored to each patient’s anatomy.”
Designed by a team of world-class surgeons, the Blueprint MR Guidance System combines Stryker's innovative software with the Microsoft HoloLens™ 2* headset, allowing the surgeon to track the position and orientation of surgical instrumentation in the physical environment. Blueprint MR Guidance allows surgeons and their instruments to be ‘guided’ by 3D images and guidance widgets, which can be displayed on the patient and in the surgeon’s line of sight without disrupting normal workflow. The MR Guidance system received FDA clearance in January 2023.
“The addition of Mixed Reality Guidance to our Blueprint platform has the potential to benefit the entire shoulder arthroplasty market – surgeons and patients alike,” said Tim Lanier, president of Stryker’s Trauma & Extremities division. “Now that Mixed Reality Guidance has officially entered the operating room, our surgeons will have access to the most innovative technology available, enabling more precise surgical results and allowing for improved results for patients.”
Blueprint Mixed Reality OR Visualization, the previous iteration of Stryker’s Blueprint Mixed Reality, has been used by over 50 surgeons and in more than 3,500 shoulder replacement procedures globally. To learn more about Blueprint and Mixed Reality, visit shoulderblueprint.com.
Stryker anticipates the completion of the first case utilizing the Blueprint® Mixed Reality (MR) Guidance System in Europe in February, marking a significant milestone in advancing surgical technology globally.
About Stryker
Stryker is a global leader in medical technologies and, together with its customers, is driven to make healthcare better. The company offers innovative products and services in MedSurg, Neurotechnology, Orthopaedics and Spine that help improve patient and healthcare outcomes. Alongside its customers around the world, Stryker impacts more than 130 million patients annually. More information is available at www.stryker.com.
____________
Mayo Clinic has a financial interest in the technology referenced in this press release. Mayo Clinic will use any revenue it receives to support its not-for-profit mission in patient care, education and research.
Dr. Joaquin Sanchez-Sotelo is a paid consultant of Stryker Trauma and ExtremitiesTrauma and Extremities. The opinions expressed by Dr. Joaquin Sanchez-Sotelo are those of Dr. Joaquin Sanchez-Sotelo and not necessarily those of Stryker. Individual experiences may vary.
A surgeon must always rely on his or her own professional clinical judgment when deciding whether to use a particular product when treating a particular patient. Stryker does not dispense medical advice and recommends that surgeons be trained in the use of any product before using it in surgery.
The information presented is intended to demonstrate the breadth of Stryker’s product offerings. A surgeon must always refer to the package insert, product label and/or instructions for use before using any of Stryker’s products. Products may not be available in all markets because product availability is subject to the regulatory and/or medical practices in individual markets. Please contact your sales representative if you have questions about the availability of products in your area.
Stryker Corporation or its divisions or other corporate affiliated entities own, use or have applied for the following trademarks or service marks: Stryker. All other trademarks are trademarks of their respective owners or holders.
Content ID: AP-017097A
Copyright © 2024 Stryker
* Used with permission from Microsoft
更多内容,请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点,如有版权侵扰或错误之处,请及时联系我们,我们会在24小时内配合处理。
靶点
-
药物
-
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台,助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台,以API或者数据包形式对外开放,助您更加充分利用智慧芽新药情报信息。